Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Callisto Pharmaceuticals Inc.

Division of Bausch Health Companies Inc.
www.callistopharma.com

Latest From Callisto Pharmaceuticals Inc.

Deals Shaping The Medical Industry, September 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Deals Of The Week: Allergan/Molecular Partners, Silence Therapeutics/MiReven, Pfizer/Mylan

The widely dispersed array of developmental therapies for conditions such as non-small cell lung cancer and type 2 diabetes begs the question of whether it would make more sense to have a biopharmaceutical industry based on solution-focused companies approaching a single problem from multiple angles.

BioPharmaceutical Deals

Synergy Pharmaceuticals raises $14 million for constipation drug trials

Nasdaq-listed Synergy Pharmaceuticals has raised just under $14 million after expenses in a public offering of shares and warrants. The company said it would use some of the proceeds to fund its gastrointestinal product R&D activities, which include an ongoing Phase II/III trial of plecanatide in chronic constipation and a Phase I trial of SP-333.

Gastrointestinal Cancer

Ironwood raises $50 million for IBS product development

Ironwood Pharmaceuticals has raised $50 million in private equity financing primarily to support the development of linaclotide, its Phase III gastrointestinal compound. The money will fund linaclotide's development in irritable bowel syndrome with constipation (IBS-C) and chronic constipation, as well as its other candidates and commercial expansion.

Gastrointestinal Cancer
See All

Company Information

UsernamePublicRestriction

Register